# Eplerenone Inhibits Atrial Autonomic Nerve Remodeling in Atrial Fibrillation Through ERK1/2 MAPK Pathway

**Authors:** Wei Xu, Cheng-yuan Yu, Ding-yu Wang, Qiang Gao, Song Zhang, Yun Zhang, Yue Yuan, Jing Shi, Yue Li, Guang-zhong Liu, Xiao-ming Shang

PMC · DOI: 10.1155/cdr/6041636 · Cardiovascular Therapeutics · 2025-07-28

## TL;DR

Eplerenone reduces nerve changes in the heart that lead to atrial fibrillation by affecting a specific signaling pathway.

## Contribution

This study reveals a new mechanism by which eplerenone prevents atrial nerve remodeling through the ERK1/2 MAPK pathway.

## Key findings

- Eplerenone reduced the activation of the ERK1/2 MAPK pathway in AF models.
- Eplerenone inhibited the expression of nerve-related growth factors and reduced AF duration.
- Eplerenone modulated circulating neurohormones and prevented atrial nerve remodeling.

## Abstract

Atrial autonomic nerve system (ANS) remodeling plays an important role in atrial fibrillation (AF). Mineralocorticoid receptor antagonists (MRAs) have been proved to be effective in preventing atrial structural remodeling. However, the effects of MRA on ANS remodeling in AF and the underlying mechanisms are still unknown.

Methods: Then, 21 rabbits were randomized into sham, pacing, and pacing + eplerenone groups. To verify the effect of aldosterone on ANS remodeling, 18 SD rats were pumped with aldosterone. HL-1 cells were subjected to control treatment or rapid pacing with or without eplerenone or U0126 (an inhibitor of ERK1/2). Atrial sympathetic and parasympathetic remodeling was detected by immunohistochemical staining, Western blotting, and RT-PCR. The circulating neurohormone and atrial electrophysiology were also assessed.

Results: The ERK1/2 MAPK pathway was significantly activated in AF rabbit/HL-1 cell models, resulting in the upregulation of key downstream protein; this effect was significantly restored by eplerenone. Eplerenone prevented the alterations in circulating neurohormone, reduced the mRNA level of sympathetic and parasympathetic-related growth factors, and inhibited the inducibility and duration of AF.

Conclusions: Eplerenone inhibited atrial autonomic nerve remodeling and the occurrence of AF through modulating the ERK1/2 MAPK pathway.

## Linked entities

- **Proteins:** erk1/2 (mitogen-activated protein kinase)
- **Chemicals:** eplerenone (PubChem CID 443872), U0126 (PubChem CID 3006531)
- **Diseases:** atrial fibrillation (MONDO:0004981)

## Full-text entities

- **Genes:** Gap43 (growth associated protein 43) [NCBI Gene 29423] {aka Basp2}, NR3C2 (nuclear receptor subfamily 3 group C member 2) [NCBI Gene 4306] {aka MCR, MLR, MR, NR3C2VIT}, Clmp (CXADR like cell adhesion molecule) [NCBI Gene 286939] {aka ACAM, Asam, Ol16}, GAP43 (growth associated protein 43) [NCBI Gene 2596] {aka B-50, GAP-43, PP46}, GJA1 (gap junction protein alpha 1) [NCBI Gene 2697] {aka AVSD3, CMDR, CX43, EKVP, EKVP3, GJAL}, Casp3 (caspase 3) [NCBI Gene 25402] {aka CPP32-beta, Lice, Yama}, ABCD1 (ATP binding cassette subfamily D member 1) [NCBI Gene 215] {aka ABC42, ALD, ALDP, AMN}, ChAT [NCBI Gene 100342226], Th (tyrosine hydroxylase) [NCBI Gene 25085] {aka The}, NGF [NCBI Gene 103350089], GJA5 (gap junction protein alpha 5) [NCBI Gene 2702] {aka ATFB11, CX40}, Gapdh (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 24383] {aka BARS-38, Gapd}, NGF (nerve growth factor) [NCBI Gene 4803] {aka Beta-NGF, HSAN5, NGFB}, Mtpn (myotrophin) [NCBI Gene 79215] {aka Gcdp}, Ngf (nerve growth factor) [NCBI Gene 310738] {aka Ngfb, beta-NGF}, Ephb1 (Eph receptor B1) [NCBI Gene 24338] {aka Ephb2, Erk, elk}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 59086] {aka Tgfb}, GAP-43 [NCBI Gene 100345603], Chat (choline O-acetyltransferase) [NCBI Gene 290567]
- **Diseases:** Atrial ANS Remodeling (MESH:D064752), OSA (MESH:C535586), cardiovascular disease (MESH:D002318), AF (MESH:D001281), arrhythmia (MESH:D001145), ischemic stroke (MESH:D002544), Fibrosis (MESH:D005355), systemic embolism (MESH:D004617)
- **Chemicals:** Eplerenone (MESH:D000077545), ACH (MESH:D000109), eosin (MESH:D004801), PBS (MESH:D007854), polyacrylamide (MESH:C016679), sodium pentobarbital (MESH:D010424), streptomycin (MESH:D013307), polyvinylidene difluoride (MESH:C024865), aldosterone (MESH:D000450), PEG (MESH:D011092), hematoxylin (MESH:D006416), xylazine (MESH:D014991), paraffin (MESH:D010232), NE (MESH:D009638), penicillin (MESH:D010406), U0126 (MESH:C113580), DAB (MESH:C000469), ALD2 (-)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Canis lupus familiaris (dog, subspecies) [taxon 9615], Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** HL-1 — Mus musculus (Mouse), Transformed cell line (CVCL_0303)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12321439/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12321439/full.md

## References

37 references — full list in the complete paper: https://tomesphere.com/paper/PMC12321439/full.md

---
Source: https://tomesphere.com/paper/PMC12321439